The Safety Specification

The Safety Specification is where an RMP defines, precisely, what it’s actually managing — and it does that through three genuinely distinct categories that are easy to blur together without careful attention. Identified risks are confirmed associations between the product and an adverse outcome, strong enough to already be reflected in the product’s label — these are, in the Module 6 sense, expected risks, documented in the CCSI, with a known profile the rest of the RMP is designed to actively manage rather than merely watch for.

Potential risks sit at an earlier stage of confidence: a plausible association that hasn’t cleared the bar for confirmation. These can originate from several places covered elsewhere in this course — preclinical toxicology findings that suggest a mechanism, a known class effect shared by pharmacologically related drugs, or a signal from Module 7 that’s been validated as worth tracking but hasn’t yet accumulated enough evidence to be classified as a confirmed, identified risk. Treating a potential risk with the same certainty as an identified one overstates the evidence; ignoring it because it isn’t yet confirmed misses exactly the kind of concern proactive risk management exists to address before it becomes a bigger problem.

Missing information is the category most often underappreciated, and it’s not simply a catch-all for "things we don’t know" — it specifically covers populations or clinical scenarios where the available data is genuinely inadequate to characterise safety with confidence: limited experience in pregnant or breastfeeding patients, in patients with significant renal or hepatic impairment, in a specific paediatric age band, or in patients on a particular combination of concomitant medications. Missing information doesn’t mean a risk exists in these populations — it means the organisation genuinely doesn’t yet know, and the RMP has to plan around that uncertainty rather than pretend it isn’t there.

Getting these three categories right matters because they drive everything that follows in the RMP: the Pharmacovigilance Plan in Part III and the Risk Minimisation Measures in Part V are both built directly off the Safety Specification’s content — an identified risk with a well-understood mechanism might warrant a straightforward label warning, while missing information in a vulnerable population might warrant a dedicated additional study rather than passive monitoring. The safety specification isn’t a preamble to the RMP; it’s the foundation everything downstream is built on.